.7 cells were exposed to 100 µg/ml unmodified and CU 2 -oxidized myelin for 24h,
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after which CL-P1 expression was determined. (h-k) RAW264.7 cells were cultured with 100 31 µg/ml unmodified or CU 2 -oxidized myelin or left untreated for 1 (h), 2 (i), 3 (j), and 8 days 32 (k). CL-P1 expression was determined by using flow cytometry. (l) RAW264.7 cells were 33 cultured with a 1 µM T0901317 (LXR agonist), 1 µM GW501516 (PPARβ/δ agonist), or 100 34 µg/ml myelin for 24h, after which CL-P1 expression was determined with flow cytometry.
35
(m,n) Untreated (m) or myelin treated RAW264.7 cells (n) were exposed to 500 U/ml IFNγ, 36 100 ng/ml LPS, a combination 500 U/ml IFNγ and 100 ng/ml LPS, or left untreated. CL-P1 37 expression was determined by using flow cytometry. directed against CL-P1 (shRNA1-4) for 48h. Next, DiI-labeled myelin was added for 1.5h.
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Flow cytometry was used to define myelin uptake. were used to define CL-P1 expression.
